AMIS in the Pharmaceutical Industry
Pharmaceutical companies and AMIS
For the past three decades, Kite, a Gilead company, has been at the forefront of cancer immunotherapy. Today, they are a leader in engineered ‘T cell therapy’, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
Benefits of The AMIS Assessment
Following the completion of the Asset Maintenance Improvement System (AMIS) Assessment results showed how even though AMIS has been established and proven for over 30-years, it is still as relevant today and is applicable to a broad range of companies, as well as, those using leading-edge technology, such as Kite.
Founded in 2005, Porton Pharma Solutions Ltd. is a top-tier, China-based external manufacturing partner and strategic supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to many of the world’s leading pharmaceutical companies. Porton helps global pharmaceutical companies efficiently deliver improved health outcomes for patients through chemical process innovation and high-quality production of intermediates and APIs across the life cycle.
The AMIS Approach
The project, for which MCP has been commissioned, is designed to take the company to World-Class status using The AMIS Journey and The AMIS Assessment, as the start of the forthcoming maintenance improvement project. This best practice standard, helps organisations measure their Asset Maintenance performance on a consistent basis.
Using the extensive AMIS database
The output generates Key Performance Indicators (KPIs) and benchmarks that are used as the basis for an improvement programme and the start of The AMIS Journey.
